CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330 - PubMed (original) (raw)
. 2014 Jan 16;123(3):356-65.
doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.
Peter Kufer, Roman Kischel, Gerhard Zugmaier, Jan Bögeholz, Thomas Köhnke, Felix S Lichtenegger, Stephanie Schneider, Klaus H Metzeler, Michael Fiegl, Karsten Spiekermann, Patrick A Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe
Affiliations
- PMID: 24300852
- DOI: 10.1182/blood-2013-08-523548
Free article
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al. Blood. 2014.
Free article
Abstract
Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging (BiTE) antibody (AMG 330) for its suitability as a therapeutic agent in acute myeloid leukemia (AML). We first assessed CD33 expression levels by flow cytometry and found expression in >99% of patient samples (n = 621). CD33 was highest expressed in AMLs with NPM1 mutations (P < .001) and lower in AMLs with complex karyotypes and t(8;21) translocations (P < .001). Furthermore, leukemic stem cells within the CD34(+)/CD38(-) compartment displayed CD33 at higher levels than healthy donor stem cells (P = .047). In MS-5 feeder cell-based long-term cultures that supported the growth of primary AML blasts for up to 36 days, AMG 330 efficiently recruited and expanded residual CD3(+)/CD45RA(-)/CCR7(+) memory T cells within the patient sample. Even at low effector to target ratios, the recruited T cells lysed autologous blasts completely in the majority of samples and substantially in the remaining samples in a time-dependent manner. This study provides the first correlation of CD33 expression levels with AML genotype in a comprehensive analysis of adult patients. Targeting CD33 ex vivo using AMG 330 in primary AML samples led to T cell recruitment and expansion and remarkable antibody-mediated cytotoxicity, suggesting efficient therapeutic potential in vivo.
Similar articles
- Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B. Friedrich M, et al. Mol Cancer Ther. 2014 Jun;13(6):1549-57. doi: 10.1158/1535-7163.MCT-13-0956. Epub 2014 Mar 27. Mol Cancer Ther. 2014. PMID: 24674885 - CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D. Jitschin R, et al. J Immunother Cancer. 2018 Nov 5;6(1):116. doi: 10.1186/s40425-018-0432-9. J Immunother Cancer. 2018. PMID: 30396365 Free PMC article. - The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB. Harrington KH, et al. PLoS One. 2015 Aug 25;10(8):e0135945. doi: 10.1371/journal.pone.0135945. eCollection 2015. PLoS One. 2015. PMID: 26305211 Free PMC article. - Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G, Klinger M, Schmidt M, Subklewe M. Zugmaier G, et al. Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13. Mol Immunol. 2015. PMID: 25883042 Review. - CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC, Stein A. Clark MC, et al. Best Pract Res Clin Haematol. 2020 Dec;33(4):101224. doi: 10.1016/j.beha.2020.101224. Epub 2020 Nov 18. Best Pract Res Clin Haematol. 2020. PMID: 33279180 Review.
Cited by
- Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy.
Fiorenza S, Lim SYT, Laszlo GS, Kimble EL, Phi TD, Lunn-Halbert MC, Kirchmeier DR, Huo J, Kiem HP, Turtle CJ, Walter RB. Fiorenza S, et al. Mol Ther Oncol. 2024 Jul 31;32(3):200854. doi: 10.1016/j.omton.2024.200854. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39224504 Free PMC article. - Breaking Boundaries: Immunotherapy for Myeloid Malignancies.
Gavrilova T, Schulz E, Mina A. Gavrilova T, et al. Cancers (Basel). 2024 Aug 6;16(16):2780. doi: 10.3390/cancers16162780. Cancers (Basel). 2024. PMID: 39199554 Free PMC article. Review. - Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
Kazerani M, Marcinek A, Philipp N, Brauchle B, Taylor JJ, Moreno HD, Terrasi A, Tast B, Rohrbacher L, Wang Y, Warm M, Emhardt AJ, Magno G, Spiekermann K, Herold T, Straub T, Theurich S, Schotta G, Kischel R, Bücklein VL, Subklewe M. Kazerani M, et al. Leukemia. 2024 Oct;38(10):2270-2275. doi: 10.1038/s41375-024-02387-4. Epub 2024 Aug 22. Leukemia. 2024. PMID: 39174782 Free PMC article. No abstract available. - Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia.
Nair R, Salinas-Illarena A, Sponheimer M, Wullkopf I, Schreiber Y, Côrte-Real JV, Del Pozo Ben A, Marterer H, Thomas D, Geisslinger G, Cinatl J Jr, Subklewe M, Baldauf HM. Nair R, et al. Clin Exp Med. 2024 Jul 13;24(1):155. doi: 10.1007/s10238-024-01425-w. Clin Exp Med. 2024. PMID: 39003408 Free PMC article. - Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191.
Lunn-Halbert MC, Laszlo GS, Erraiss S, Orr MT, Jessup HK, Thomas HJ, Chan H, Jahromi MA, Lloyd J, Cheung AF, Chang GP, Dichwalkar T, Fallon D, Grinberg A, Rodríguez-Arbolí E, Lim SYT, Kehret AR, Huo J, Cole FM, Scharffenberger SC, Walter RB. Lunn-Halbert MC, et al. Cancers (Basel). 2024 Feb 22;16(5):877. doi: 10.3390/cancers16050877. Cancers (Basel). 2024. PMID: 38473239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials